Optimization and Classification of Solid Dispersion of Piroxicam by Mixed Solvency Model
Keywords:
Piroxicam, Solid Dispersion, Solubility, Mixed Solvency Concept.Abstract
In this examination traditional piroxicam container has moderate beginning of activity (45-60 min) and helpless bioavailability (50-60%), and along these lines can't be given in crisis clinical circumstances like postoperative agony, rheumatoid joint inflammation or osteoarthritis. So, motivation behind research was to give a quick dissolving oral dose type of piroxicam, which can give speedy beginning of activity by utilizing blended dissolvability idea. First did at first dissolvability of piroxicam was resolved separately in 3 hydrotropic specialists like sodium benzoate, sodium citrate, niacinamide and 4 water solvent polymer in particular hydroxy propyl beta cyclodextrin, PVP K30, PEG400, PEG8000 at convergence of 40% w/v arrangements utilizing decontaminated water as dissolvable. Most elevated dissolvability was gotten in 40% sodium benzoate arrangement. At that point various mixes of 2, 3 and 4 hydrotropic agents+water dissolvable polymer in various proportions were utilized to decide dissolvability, so that all out grouping of solubilizer mix was consistently 40%. Most elevated dissolvability was gotten in arrangement of sodium benzoate+HP-BCD+PVP K30 at optimum ratio of 15:15:10. This enhanced blend was used in getting ready strong scatterings arranged by blended dissolvability idea utilizing refined water as dissolvable arranged SD perform by in vitro disintegration study and described by XRD, SEM, FTIR, DSC examination.
How to cite this article:
Panwar M, Gupta P. Optimization and Classification of Solid Dispersion of Piroxicam by Mixed Solvency Model. J Adv Res NanoSci NanoTech 2021; 3(1): 00-00.
References
Chiou W.L. and Riegelman S. “Pharmaceutical applications of solid dispersion systems” Journal of Pharmaceutical Sciences, 60: 1281-1302,(1971).
Fernandez M., Margarit M.V., Rodriguez I.C. and Cerezo A.“Dissolution kinetics of piroxicam in solid dispersion with polyethylene glycol 4000.”International Journal of Pharmaceutics, 98: 29-35,(1993).
Sharma D.K.,Gupta V.B. and Purohit S. ”Industry feasible method to improve solubility of Piroxicam with Crospovidone.”Der Pharmacia Lettre, 2(3): 123-135, (2010).
Maheshwari R.K. and Jagwani Y.“Mixed Hydrotropy: Novel Science of Solubility Enhancement.”Indian Journal of Pharmaceutical Sciences,73(2): 179–183,(2011).
Maheshwari R.K. “Solubilization of ibuprofen by mixed solvency approach.” The Indian pharmacist, 8(87) : 81-84,(2009).
Maheshwari R.K. “Mixed-solvency approach – boon for solubilisation of poorly water-soluble drugs.”Asian journal of pharmaceutics,4 :60-63,(2010).
Maheshwari R.K. “Potentiation of solvent character by mixed-solvency concept :a novel concept of solubilisation.” Journal of pharmacy research, 3(2): 411-413,(2010).
JingLi., KeWu., Wayne W., Denita A. and Winstead G. “Formation and Characterization of Solid Dispersions ofPiroxicam and Polyvinylpyrrolidone Using Spray Drying and Precipitation with Compressed Antisolvent.”Journal of pharmaceutical sciences,98(7): 2422-2431,(2009).
Rawat S.S. and Jain N.K.“Hydrotropic solubilization of some cox-2 inhibitors” Indian Drugs, 43: 565-574, (2006).
Shah P.P. and Rajashree C.M.“Development and Evaluation of Artemether Taste Masked Rapid Disintegrating Tablets with Improved Dissolution Using Solid Dispersion Technique.”AAPS Pharmaceutical Sciences Technology, 9 (2): 494-500,(2008).
Rao M., Mandage Y., Khole I. and Munjapara G. “Characterization of Solid Dispersions of Simvastatin with PVP K30 andPoloxamer 188.” Indian Journal of Pharmaceutical Education and Research, 45(2): 145-152,(2011).
Tantishaiyakul V., Kaewnopparat N. and Ingkatawornwong S.“Properties of solid dispersion of piroxicam in polyvinylpyrrolidone.” International Journal of Pharmaceutics, 181: 143-151, (1999).
Published
Issue
Section
Copyright (c) 2021 Journal of Advanced Research in Nanoscience and Nanotechnology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
